Megan Bailey

Megan Bailey has served as Labcorp’s Executive Vice President and President, Central Laboratory Services and International since 2024. 

Previously, she served as Labcorp’s Executive Vice President and Chief Strategy and Transformation Officer where she led efforts to define Labcorp’s future growth strategy.

Mark Schroeder

Mark Schroeder has served as Labcorp’s Executive Vice President and President, Diagnostics and Chief Operations Officer since 2023. 

In this role, Mark leads all Diagnostics divisions and commercial teams, as well as routine and esoteric testing laboratory operations for Labcorp Diagnostics and global supply chain.

Lance Berberian

In October 2024, Lance Berberian announced his planned retirement from Labcorp in 2025. Lance served as Executive Vice President and Chief Information and Technology Officer from 2014 through October 2024. In November 2024, he stepped into the role of Special Advisor, Strategy. In this role he is working directly with the CEO and the executive team to drive the development and implementation of Labcorp’s enterprise strategy.

Glenn Eisenberg

Glenn Eisenberg has served as Executive Vice President and Chief Financial Officer of Labcorp since 2014.

Brian Caveney, M.D., J.D., M.P.H.

EVP and President, Early Development Research Laboratories

Brian Caveney, M.D. has served as Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer at Labcorp since 2023.

In his current role, Brian leads all early development research laboratories globally and oversees all medical and scientific affairs, oncology, cell and gene therapy, and quality for Labcorp.

Anita Graham

Anita Graham has served as Executive Vice President and Chief Human Resources Officer since 2023.

Amy Summy

Amy Summy has served as Executive Vice President and Chief Marketing Officer since March 2020.

Adam Schechter

Global business leader Adam Schechter became Chief Executive Officer of Labcorp in November 2019 and Chairman of the Board in May 2020. Prior to that, he was named Lead Independent Director in January 2019 after serving as a director of the company since 2013.

2024 Developments in Cardiometabolic Care for the Busy Primary Care Physician

The primary care team, including nurse practitioners and physician assistants, is often the first to evaluate and assess chronic conditions and interconnected comorbidities, such as steatotic liver disease, renal disease and Type 2 diabetes (T2D), using diagnostic assays. Use of evidence-based strategies for early detection and effective management of cardiovascular-kidney-metabolic (CKM) conditions is crucial for optimal patient outcomes.

Navigating the nontraditional: A look into fertility challenges and novel referral indications

Hear our subject matter experts share fertility-focused case studies that highlight the challenges and available options for nontraditional families, novel referral indications and how genetic counselors can support patients.